ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Jan 2026
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
February 2026
Nuclear Technology
January 2026
Fusion Science and Technology
November 2025
Latest News
Jeff Place on INPO’s strategy for industry growth
As executive vice president for industry strategy at the Institute of Nuclear Power Operations, Jeff Place leads INPO’s industry-facing work, engaging directly with chief nuclear officers.
R. G. Alsmiller, Jr., J. Barish, R. T. Santoro, R. A. Lillie, J. M. Barnes, M. M. H. Ragheb
Nuclear Technology | Volume 48 | Number 3 | May 1980 | Pages 187-195
Technical Paper | Reactor | doi.org/10.13182/NT80-A32466
Articles are hosted by Taylor and Francis Online.
Calculated dose rates in the Tokamak Fusion Test Reactor test cell from induced activity have been obtained. The dose rates for the case of no neutral beam injector and when a neutral beam injector (with the resultant large penetration through the primary shield) is present are given separately. The photon transport calculations are carried out using Monte Carlo techniques, since this greatly facilitates the consideration of different pulse sequences and times after reactor shutdown. Dose rates are given for several different deuterium-tritium pulse sequences and for a variety of times after the reactor is turned off. At a few positions in the test cell, the contribution to the dose rates from individual residual nuclei is also presented. In general, it is found that the presence of the shielded neutral beam injector does not have a large effect on the dose rates in the test cell.